NASDAQ:CBIO Crescent Biopharma Q2 2026 Earnings Report $14.47 -0.55 (-3.66%) Closing price 07/31/2026 04:00 PM EasternExtended Trading$15.03 +0.56 (+3.86%) As of 07/31/2026 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Crescent Biopharma EPS ResultsActual EPS-$0.74Consensus EPS -$0.74Beat/MissMissed by -$0.00One Year Ago EPSN/ACrescent Biopharma Revenue ResultsActual RevenueN/AExpected Revenue$0.36 millionBeat/MissN/AYoY Revenue GrowthN/ACrescent Biopharma Announcement DetailsQuarterQ2 2026Date7/30/2026TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Crescent Biopharma Earnings HeadlinesCrescent Biopharma, Inc. (NASDAQ:CBIO) Receives $29.40 Consensus Target Price from AnalystsAugust 1 at 3:15 AM | americanbankingnews.comCrescent Biopharma Reports Q2 2026 Results and Advances Clinical Development of CR-001, CR-002 and CR-003 July 30 at 7:51 AM | quiverquant.comQ7 Bankers Met in Secret (Now We Pay for It)A little-known meeting in 1910 cost the average American family their entire financial freedom. They met in secret, used fake names, and told absolutely no one where they were going. On November 22nd, 1910, seven of America's most powerful bankers gathered on Jekyll Island to design the Federal Reserve. Their goal? To create a system where they control the money supply and you foot the bill. That system has created $38 trillion in debt, destroyed 98% of the dollar's purchasing power, and now they're preparing the final move: Central bank digital currencies (CBDCs). But if you have at least $100,000 saved and you're concerned about what's coming, you need to hear this.August 2 at 1:00 AM | Decentralized Masters (Ad)Crescent Biopharma Reports Second Quarter 2026 Financial Results and Recent Business HighlightsJuly 30 at 7:35 AM | globenewswire.comCrescent Biopharma Announces Grants of Inducement AwardsJuly 23, 2026 | globenewswire.comCrescent Biopharma Announces Closing of Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of Underwriters' Option to Purchase Additional SharesJuly 16, 2026 | globenewswire.comSee More Crescent Biopharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Crescent Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Crescent Biopharma and other key companies, straight to your email. Email Address About Crescent BiopharmaCrescent Biopharma (NASDAQ:CBIO) (NASDAQ: CBIO) is a clinical‐stage immuno‐oncology company focused on the discovery, development and commercialization of novel therapies for patients with solid tumors. The company’s research strategy centers on combination approaches that enhance anti‐tumor immune responses by simultaneously targeting multiple pathways implicated in immune evasion and tumor growth. The company’s lead candidate, CPB-201, is a bifunctional fusion protein designed to block programmed death-ligand 1 (PD-L1) while neutralizing transforming growth factor-beta (TGF-β), with the goal of restoring T-cell activity and reducing tumor fibrosis. In parallel, Crescent is advancing an oncolytic adenovirus program engineered to selectively infect and lyse cancer cells, thereby releasing tumor antigens and amplifying systemic immune responses. Additional preclinical assets explore complementary mechanisms to address resistance in solid tumors. Research and development activities are conducted primarily in the United States, leveraging a proprietary platform that integrates molecular engineering with immuno‐oncology expertise. Crescent collaborates with contract research organizations and academic institutions to optimize candidate selection, advance preclinical studies and prepare for clinical evaluation. Founded in 2020 and headquartered in Woodland Hills, California, Crescent Biopharma is led by a management team and scientific advisory board with extensive experience in oncology drug discovery, biologics development and clinical operations. The company is focused on progressing its pipeline through IND-enabling studies and early‐phase clinical trials.View Crescent Biopharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 07/27- 07/31Chevron’s Strong Quarter Shows Why It Still Leads the Energy SectorNetflix's Big Sell-Off May Be Sending the Wrong SignalAmazon’s Earnings Beat Shows Why AWS Is Back at the Center of the Bull CaseApple’s Record Quarter Could Not Outrun Its Guidance ProblemPopular’s Earnings Beat Shows Why This Bank Stock Keeps ClimbingMicrosoft Just Flipped the AI Spending Narrative Overnight Upcoming Earnings Booking (8/3/2026)Marriott International (8/3/2026)Diamondback Energy (8/3/2026)ONEOK (8/3/2026)Williams Companies (8/3/2026)Mitsubishi UFJ Financial Group (8/3/2026)Vertex Pharmaceuticals (8/3/2026)Palantir Technologies (8/3/2026)Spotify Technology (8/4/2026)SpaceX (8/4/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
